Citius Oncology, Inc. Cash Flow Conversion Efficiency
Citius Oncology, Inc. cash flow conversion efficiency. Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has a cash flow conversion efficiency ratio of -0.071x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.85 Million) by net assets ($40.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Citius Oncology, Inc. (2022–2025)
Cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025. This chart illustrates how Citius Oncology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Citius Oncology, Inc. (CTOR) share price today for real-time trading data and today's change.
Citius Oncology, Inc. Cash Flow Conversion Ratio Explained
Citius Oncology, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Citius Oncology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Oncology, Inc. ranked by their cash flow conversion efficiency. Also see market value of Citius Oncology, Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Loulis Mills S.A.
AT:KYLO
|
0.049x |
|
A SPAC II Acquisition Corp.
NASDAQ:ASCBF
|
-0.005x |
|
Archer Materials Limited
F:38A
|
-0.028x |
|
Healthcare AI Acquisition Corp
NASDAQ:HAIA
|
-0.031x |
|
Fecon Foundation Engineering and Underground Construction JSC
VN:FCN
|
0.096x |
|
BenQ Medical Technology
TWO:4116
|
0.065x |
|
Sheetal Cool Products Limited
NSE:SCPL
|
0.030x |
|
Youngbo Chem
KO:014440
|
0.027x |
Annual Cash Flow Conversion Efficiency for Citius Oncology, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025. Review Citius Oncology, Inc. (CTOR) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $44.87 Million | $-5.49 Million | -0.122x | -4570.02% |
| 2024-09-30 | $46.14 Million | $126.35K | 0.003x | +111.63% |
| 2023-09-30 | $25.54 Million | $-601.30K | -0.024x | -1680.38% |
| 2022-09-30 | $36.27 Million | $-47.97K | -0.001x | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary… Read more